A few news bits and data points are spotlighting the big potential in China’s healthcare market over the next few years for companies that can tap into an overhaul of the national medical system. While that news looks good for healthcare companies overall, the limited universe of publicly traded firms available to western investors looks a bit spottier due to individual company issues. Regulatory issues could also be a risk, as highlighted by a new price fixing ruling against US drug giant Johnson & Johnson (NYSE: JJ). Still, there could be some interesting buying opportunities for the right companies. Read Full Post…
A few interesting news bits on the medical front are spotlighting both the opportunities and risks that drug and medical equipment makers face in developing the China market. On the opportunity side, Bristol-Myers Squibb (NYSE: BMY) has announced an expansion of its relationship with Simcere Pharmaceutical (NYSE: SCR) to introduce its drugs into China. Meantime, homegrown medical equipment maker Mindray Medical (NYSE: MR) is also banking on the market’s potential with its newly announced acquisition of a US ultrasound equipment maker. But US drug giant Johnson & Johnson (NYSE: JNJ) is also finding the market contains some risks, as it comes under fire for double standards related to its product recall policies in China. Read Full Post…
The following press releases and media reports about Chinese companies were carried on June 15-17. To view a full article or story, click on the link next to the headline.
══════════════════════════════════════════════════════
EU Free-Trade States Urge Quick Resolution Of Chinese Solar Dispute (English article)
Beijing Warns Johnson & Johnson (NYSE: JNJ) Over Recall Double Standards (English article)
Bristol-Myers, Simcere (NYSE: SCR) To Co-Develop Orencia In China (PRNewswire)
Ming Yang (NYSE: MY) Announces Change Of CFO (PRNewswire)
Smithfield (NYSE: SFD) Profit Plunges After China Blocks Imports (English article)
